Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

Abstract Background Chimeric antigen receptor (CAR)-engineered T cells have demonstrated promising clinical efficacy in patients with B cell lymphoma. However, the application of CAR-T cell therapy in the treatment of other solid tumors has been limited. We incorporated 4-1BB into the anti-GD2 CAR-T...

Full description

Bibliographic Details
Main Authors: Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Zhihong Chi, Xinan Sheng, Lu Si, Chuanliang Cui, Jie Dai, Meng Ma, Tianxiao Xu, Yan Kong, Jun Guo
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Journal of Hematology & Oncology
Subjects:
CAR-T
GD2
4-1BB
Melanoma
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s13045-017-0548-2

Internet

http://link.springer.com/article/10.1186/s13045-017-0548-2

Similar Items